Orion - Company Announcement

Orion upgrades full-year outlook for 2011

ORION CORPORATION STOCK EXCHANGE RELEASE 13 April 2011 at 5.02 p.m. EEST

Orion Corporation upgrades the full-year outlook estimate for 2011 provided in
the Financial Statement Release 2010 and published on 9 February 2011. The
company estimates that well-developed sales in early 2011 will also reflect on
the development of full-year operating profit.

New full-year outlook estimate for 2011, provided on 13 April 2011

Net sales will be slightly higher than in 2010.

Marketing expenditure will be higher due to the increased number of product
launches. Research expenditure will be higher than in 2010.

Operating profit excluding non-recurring items will be higher than in 2010.

The Group's capital expenditure will be about EUR 45 million excluding
substantial corporate or product acquisitions.

Previous full-year outlook for 2011, provided in Financial Statement Release
2010

Net sales will be slightly higher than in 2010.

Marketing expenditure will be slightly higher due to the increased number of
product launches. Research expenditure will be clearly higher than in 2010.

Operating profit excluding non-recurring items will be slightly higher than in
2010.

The Group's capital expenditure will be about EUR 45 million excluding
substantial corporate or product acquisitions.

Orion will publish the Interim Report January-March 2011 on Wednesday, 27 April
2011.



Orion Corporation


Timo Lappalainen  Olli Huotari
President and CEO SVP, Corporate Functions



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.

The Group's net sales in 2010 amounted to approximately EUR 850 million. The
Company invested EUR 85 million in research and development. At the end of
2010, the Group had a total of approximately 3,100 employees, of whom 2,450
worked in Finland and 650 in other countries. Orion's A and B shares are listed
on NASDAQ OMX Helsinki.




[HUG#1505959]